How DCN Dx’s Clinical Research Team Met an Unmovable Deadline and Delivered Full Regulatory Success
This case study details how DCN Dx’s Clinical Research Services (CRS) division helped a sponsor fast-track a novel hepatitis C virus (HCV) molecular point-of-care test through a complex de novo authorization process—on a federal contract timeline with zero flexibility.
With just six months from kickoff to submission, DCN Dx executed a full clinical program involving over 15 hospital-affiliated sites, weekly biostatistical analysis, and real-time data management. The project team launched startup activities in parallel, solved enrollment issues through creative engagement strategies, and accelerated the entire workflow. Their efforts resulted in FDA clearance just three weeks after submission.
For sponsors facing aggressive timelines and high regulatory pressure, this case study shows how the right clinical research partner makes the difference.
WHY READ
This case study is essential for diagnostic developers with tight timelines and regulatory complexity. You’ll learn how DCN Dx helped:
- Complete a full clinical study under a non-negotiable six-month deadline.
- Coordinate over 15 clinical sites with real-time monitoring and troubleshooting.
- Implement study-specific strategies to drive subject enrollment.
- Deliver high-quality data for de novo submission and clearance.
- Prove that even the most ambitious regulatory goals can be met with expert planning and execution.
